Fludeoxyglucose F18 (FDG) PET scans are a vital diagnostic tool in modern medicine, leveraging a radioactive tracer to visualize metabolic activity within the body. As a glucose analog, FDG illuminates tissues with altered glucose metabolism, making it invaluable for detecting and monitoring a range of conditions, from malignancies to neurological disorders. This article delves into the intricacies of Fdg Pet Scans, providing an in-depth look at their indications, mechanism of action, administration, and crucial safety considerations for both patients and healthcare professionals.
Indications for FDG PET Scans
FDG PET scans, utilizing the positron-emitting radiotracer Fludeoxyglucose F18, are instrumental in both diagnosing and monitoring diverse medical conditions. While conventional imaging techniques like X-rays, CT scans, and MRIs excel at detailed anatomical visualization, FDG PET scans offer a complementary perspective by revealing functional metabolic activity, often preceding structural changes identifiable through other methods. This is particularly beneficial in early disease detection and understanding the physiological impact of various illnesses.
Neurological Applications: In neurology, FDG PET scans are FDA-approved for pinpointing areas of abnormal glucose metabolism associated with epileptic seizure foci. Beyond epilepsy, they play a significant role in visualizing metabolic changes across different brain regions, aiding in the diagnosis of neurological conditions such as Alzheimer’s disease and traumatic brain injury. The ability to assess cerebral glucose metabolism provides critical insights into brain function and dysfunction.
Oncological Applications: FDG PET scans are a cornerstone in oncology, holding FDA approval for evaluating, staging, and monitoring treatment responses across a spectrum of cancers. These include prevalent malignancies like non-small cell lung cancer, lymphomas, colorectal carcinoma, malignant melanoma, esophageal carcinoma, head and neck cancers, thyroid carcinoma, and breast cancer. The heightened glucose metabolism of cancer cells makes FDG PET scans exceptionally effective in identifying tumors, assessing their spread, and determining treatment efficacy.
Cardiological Applications: In cardiology, FDG PET scans are FDA-approved for identifying viable left ventricular myocardium exhibiting residual glucose metabolism, especially in conjunction with myocardial perfusion imaging. This is crucial for evaluating left ventricular dysfunction. Furthermore, FDG PET scans can visualize atherosclerosis by detecting macrophage accumulation and myocardial ischemia, offering insights into cardiovascular health beyond structural assessments.
Inflammatory Condition Applications: The application of FDG PET scans extends to infectious and inflammatory diseases, proving valuable in diagnosing orthopedic infections, rheumatologic conditions, osteomyelitis, ileitis, and vasculitis. Their ability to highlight areas of increased metabolic activity due to inflammation makes them a powerful tool in managing these complex conditions.
Mechanism of Action: How FDG PET Scans Work
FDG PET scans hinge on the principle of glucose metabolism and the unique properties of Fludeoxyglucose F18. Glucose metabolism begins with hexokinases, enzymes that initiate cellular glucose uptake by converting glucose into glucose-6-phosphate. This process creates a concentration gradient, facilitating further glucose diffusion into cells via glucose transporters (GLUTs). Crucially, glucose-6-phosphate is trapped within the cell, as it is impermeable to diffusion.
FDG, being a glucose analog, enters cells through GLUT transporters (primarily GLUT1 and GLUT3). However, unlike glucose, FDG lacks a hydroxyl group at the 2-C position, replaced instead with the radioactive tracer fluorine-18. Once inside the cell, FDG is phosphorylated but cannot be further metabolized. While healthy cells possess glucose-6-phosphatase to dephosphorylate and release FDG, tumor cells typically have insufficient levels of this enzyme. This, coupled with the overexpression of glucose transporters and elevated glycolysis rates in tumor cells (the Warburg effect), leads to a significantly higher accumulation of FDG in malignant tissues compared to healthy tissues.
The fluorine-18 tracer in FDG emits positrons, which, upon collision with electrons, undergo annihilation, converting mass into energy in the form of two photons. PET scanners detect these photons using scintillation crystals, converting the light emitted into electrical signals, ultimately creating images that reflect the spatial distribution of FDG and, consequently, glucose metabolism rates.
Neoplastic Disease and FDG Uptake: Metabolic alterations in neoplastic cells often precede changes in tumor size, making FDG PET scans a valuable early diagnostic and treatment monitoring tool in oncology. The Warburg effect, characterized by aerobic glycolysis in cancer cells, increases glucose transporter activity and hexokinase expression while decreasing glucose-6-phosphatase expression. This metabolic shift results in enhanced FDG uptake by malignant cells, readily detectable by PET scans. FDG PET scans can also differentiate between radiation necrosis, edema, and tumor recurrence post-radiation therapy, aiding in accurate post-treatment assessments.
Epilepsy and Brain Metabolism: The brain’s reliance on glucose as its primary energy source makes FDG PET scans particularly useful in neurology. In epilepsy, seizure foci exhibit hypermetabolism during seizures (ictal state) and hypometabolism between seizures (interictal state). FDG PET scans can identify these metabolic changes, helping localize seizure origins and providing broader insights into brain function beyond the seizure focus.
Alzheimer’s Disease and Neurodegeneration: FDG PET scans can distinguish Alzheimer’s disease from frontotemporal dementia and differentiate neurodegenerative conditions from non-neurodegenerative conditions like depression. Alzheimer’s disease is characterized by reduced glucose metabolism in the temporoparietal regions of the brain. Early detection of these metabolic changes via FDG PET scans is crucial for timely intervention, as Alzheimer’s drugs are most effective in the early stages before significant cortical atrophy occurs.
Myocardial Viability and Cardiac Metabolism: Healthy myocardium primarily utilizes fatty acids for energy. However, ischemic myocardium shifts to anaerobic glucose metabolism. FDG PET scans are used to identify hibernating myocardium in patients with left ventricular dysfunction and coronary artery disease, especially when considering revascularization. Viable, reversibly injured myocytes can metabolize glucose and accumulate FDG. Areas with reduced perfusion but high FDG uptake (perfusion-metabolism mismatch) indicate reversible dysfunction. Conversely, areas with matched reduction in both perfusion and FDG uptake suggest irreversible damage or scarring, with lower potential for recovery post-revascularization.
Atherosclerosis and Vascular Inflammation: Atherosclerotic vessels demonstrate FDG uptake, particularly within the intima of large arteries. This uptake reflects increased metabolic activity by macrophages within atherosclerotic plaques and by smooth muscle cells in arterial walls, allowing FDG PET scans to visualize vascular inflammation and metabolic changes associated with atherosclerosis.
Infectious and Inflammatory Processes and Immune Response: Inflammatory cells exhibit high glycolysis rates, leading to FDG accumulation. FDG PET scans are valuable for detecting infection and inflammation sites, particularly in orthopedic infections like osteomyelitis and prosthetic joint infections. They are also useful in evaluating other inflammatory conditions such as sarcoidosis, vasculitis, rheumatologic diseases, and ileitis.
Administration of FDG PET Scans
FDG is administered intravenously, typically 30 to 60 minutes before imaging. As a radioactive tracer, the dosage is measured in millicuries (mCi) or megabecquerels (MBq). The required dose is calculated considering radioactive decay, as fluorine-18 has a half-life of approximately 110 minutes. For adults (70 kg), the standard dose ranges from 5 to 10 mCi (185 to 370 MBq) for oncology, cardiology, and neurology applications. Pediatric doses are adjusted, typically around 2.6 mCi (96.2 MBq), although optimal pediatric dosing is not solely weight-based.
Patient Preparation is Key: Proper patient preparation is paramount for optimal image quality. Patients are required to fast for 4 to 6 hours prior to FDG administration to ensure controlled glucose levels. Blood glucose levels should be within acceptable limits on the day of the scan and ideally for the preceding two days. Uncontrolled blood glucose can lead to suboptimal image quality.
For cardiac FDG PET scans assessing myocardial ischemia, a glucose load (50 to 75g) 1 to 2 hours before FDG injection can enhance the visualization of myocardial ischemia by promoting glucose uptake in healthy myocardium. Patients are instructed to remain inactive after FDG injection, as muscle activity can lead to FDG accumulation in skeletal muscles, interfering with image interpretation. Hyperventilation and stress-induced muscle tension should also be avoided to prevent unwanted FDG uptake in the diaphragm and trapezius/paraspinal muscles, respectively.
Special Populations and Considerations:
- Hepatic Impairment: FDG pharmacokinetics in patients with hepatic impairment are not well-studied, requiring careful consideration.
- Renal Impairment: Renal impairment is not a contraindication, but it can affect image quality, potentially leading to misinterpretations due to altered FDG distribution.
- Pregnancy: FDG PET scans during pregnancy require careful benefit-risk assessment due to fetal radiation exposure. If non-emergent, scans are ideally scheduled within 10 days of menses onset.
- Breastfeeding: Minimal FDG excretion into breast milk allows breastfeeding to continue, but temporary separation (12 hours) post-injection is advised to minimize infant exposure.
- Diabetes: Patients with diabetes should have well-controlled blood glucose for at least two days prior to the scan. For oncology imaging, scans may be rescheduled if glucose levels are excessively high (>120 mg/dL) due to glucose competition with FDG uptake in tumors. However, for inflammation imaging, strict glucose control is less critical as false negatives are less likely.
- COVID-19 Vaccination: Recent COVID-19 vaccination can cause transient FDG uptake in axillary, supraclavicular, and cervical lymph nodes ipsilateral to the vaccination site. This can complicate image interpretation, particularly in cancer patients. It is crucial to document vaccination history (date, site, vaccine type). Vaccination in the contralateral arm may be considered for patients with breast, head, or neck cancers.
Adverse Effects of FDG PET Scans
Adverse reactions to FDG are rare and typically mild. Reported effects include hyperglycemia or hypoglycemia, transient hypotension, and transient increases in alkaline phosphatase. Anaphylaxis, although infrequent, has been reported, necessitating the availability of emergency resuscitation equipment and trained personnel.
Contraindications for FDG PET Scans
The primary contraindication is hypersensitivity to fludeoxyglucose or any components of its formulation. Radiation safety is a critical consideration. Minimizing radiation exposure to staff and other patients requires specialized facilities, workflow protocols, and potentially designated “hot waiting rooms” to separate FDG PET/CT patients and minimize unnecessary contact.
Monitoring During and After FDG PET Scans
FDG uptake reflects glucose metabolism rates. Organs with high glycolytic activity, such as the brain, typically show the highest FDG accumulation. Moderate uptake is also observed in the liver, spleen, thyroid, gut, and bone marrow. Active skeletal muscles also accumulate FDG. FDG is primarily cleared unchanged in urine within 24 hours. In oncology and neurology, suboptimal imaging can occur in patients with poorly controlled blood glucose, emphasizing the importance of pre-scan glucose monitoring and management.
Toxicity of FDG
Long-term toxicity studies, including carcinogenicity, mutagenicity, and fertility effects, have not been conducted for fludeoxyglucose in animal models.
Enhancing Healthcare Team Outcomes for FDG PET Scans
FDG PET scans are often integrated with CT scans (PET/CT) to combine metabolic and anatomical information, enhancing diagnostic accuracy and lesion localization. Optimizing FDG PET/CT studies requires a collaborative, interprofessional approach involving physicians, nuclear medicine specialists, technologists, and medical physicists.
Patient Preparation Optimization: Standardized patient preparation protocols are essential. Pre-scan instructions include dietary restrictions (light meal evening before, fasting after midnight for morning scans; light breakfast before 8 am for afternoon scans), hydration (1 liter of water 2 hours prior), and activity limitations (avoiding exercise for at least 6 hours pre-scan). Maintaining a calm and quiet environment during FDG injection minimizes brain activity and muscle uptake. Keeping patients warm prevents brown fat FDG uptake.
For diabetic patients, afternoon scan scheduling is preferable, maintaining fasting protocols and medication regimens. Blood glucose checks are crucial upon arrival and prior to FDG administration using calibrated glucometers. Insulin administration should be avoided within 4 hours of FDG injection for tumor imaging to prevent muscle uptake interference. Conversely, for cardiac imaging, glucose loading and insulin can enhance image quality. Glucocorticoid use should be reviewed and potentially deferred prior to vasculitis imaging, unless clinically contraindicated.
Essential Materials and Clinical Information:
- Triple-channel IV systems facilitate tracer administration and saline flushes.
- Bedside glucose meters are necessary for immediate glucose checks, although calibrated lab methods are needed for accurate SUV correction.
- Accredited weighing scales for precise patient weight measurements.
- Comprehensive clinical information is vital, including:
- PET/CT indication
- Patient height and weight
- Tumor type and site
- Prior tumor history and comorbidities
- Previous imaging results (CT, MRI)
- Allergies
- Diabetes status and medications
- Treatment history (dates, types) if monitoring therapy response
- Kidney function
Preparation and Administration Best Practices: Staff handling radiopharmaceuticals require competency-based training in dose dispensing, calibration, safety, and aseptic techniques. Radiation shielding and waterproof gloves are mandatory during drug handling. Indwelling IV lines, three-way valves, and saline flushes are standard for administration. Automated administration systems should be calibrated to ensure accurate dose delivery (within 3%). Patients should be positioned comfortably and instructed to void shortly before imaging.
Interprofessional collaboration, as emphasized by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), is crucial. Supervision by a nuclear medicine physician (or qualified radiologist with nuclear medicine training) is recommended. Certified nuclear medicine technologists should perform the scans, and medical physicists play a vital role in protocol optimization, quality assurance, and radiation safety. This team-based approach optimizes image quality, minimizes radiation exposure, and ultimately enhances patient outcomes from FDG PET/CT imaging.
References
1.Tai YF, Piccini P. Applications of positron emission tomography (PET) in neurology. J Neurol Neurosurg Psychiatry. 2004 May;75(5):669-76. [PMC free article: PMC1763584] [PubMed: 15090557]
2.Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979 Jan;44(1):127-37. [PubMed: 363301]
3.Newberg A, Alavi A, Reivich M. Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Semin Nucl Med. 2002 Jan;32(1):13-34. [PubMed: 11839066]
4.Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004 May;231(2):305-32. [PubMed: 15044750]
5.Otsuka H, Graham M, Kubo A, Nishitani H. Clinical utility of FDG PET. J Med Invest. 2004 Feb;51(1-2):14-9. [PubMed: 15000251]
6.Anagnostopoulos C, Georgakopoulos A, Pianou N, Nekolla SG. Assessment of myocardial perfusion and viability by positron emission tomography. Int J Cardiol. 2013 Sep 01;167(5):1737-49. [PubMed: 23313467]
7.Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, Israel O, Martin-Comin J, Signore A. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013 Apr;54(4):647-58. [PubMed: 23359660]
8.Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med. 2004 Jun;45(6):930-2. [PubMed: 15181126]
9.Suolinna EM, Haaparanta M, Paul R, Härkönen P, Solin O, Sipilä H. Metabolism of 2-[18F]fluoro-2-deoxyglucose in tumor-bearing rats: chromatographic and enzymatic studies. Int J Rad Appl Instrum B. 1986;13(5):577-81. [PubMed: 3818323]
10.Berger A. How does it work? Positron emission tomography. BMJ. 2003 Jun 28;326(7404):1449. [PMC free article: PMC1126321] [PubMed: 12829560]
11.Groheux D. Role of Fludeoxyglucose in Breast Cancer: Treatment Response. PET Clin. 2018 Jul;13(3):395-414. [PubMed: 30100078]
12.Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016 Mar;41(3):211-218. [PubMed: 26778478]
13.Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr. 1987 Jul-Aug;11(4):563-70. [PubMed: 3496366]
14.Sarikaya I. PET studies in epilepsy. Am J Nucl Med Mol Imaging. 2015;5(5):416-30. [PMC free article: PMC4620171] [PubMed: 26550535]
15.Graff-Radford NR, Jones DT. Normal Pressure Hydrocephalus. Continuum (Minneap Minn). 2019 Feb;25(1):165-186. [PubMed: 30707192]
16.Khalaf S, Chamsi-Pasha M, Al-Mallah MH. Assessment of myocardial viability by PET. Curr Opin Cardiol. 2019 Sep;34(5):466-472. [PubMed: 31393420]
17.Rosenbaum D, Millon A, Fayad ZA. Molecular imaging in atherosclerosis: FDG PET. Curr Atheroscler Rep. 2012 Oct;14(5):429-37. [PMC free article: PMC3576137] [PubMed: 22872371]
18.Alavi A, Kung JW, Zhuang H. Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med. 2004 Jan;34(1):56-69. [PubMed: 14735459]
19.Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues. Ann Nucl Med. 2007 Jun;21(4):217-22. [PubMed: 17581720]
20.Zanotti-Fregonara P, Jan S, Taieb D, Cammilleri S, Trébossen R, Hindié E, Mundler O. Absorbed 18F-FDG dose to the fetus during early pregnancy. J Nucl Med. 2010 May;51(5):803-5. [PubMed: 20395321]
21.Langen KJ, Braun U, Rota Kops E, Herzog H, Kuwert T, Nebeling B, Feinendegen LE. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993 Mar;34(3):355-9. [PubMed: 8441023]
22.Rabkin Z, Israel O, Keidar Z. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis. J Nucl Med. 2010 Jul;51(7):1015-20. [PubMed: 20554733]
23.McIntosh LJ, Bankier AA, Vijayaraghavan GR, Licho R, Rosen MP. COVID-19 Vaccination-Related Uptake on FDG PET/CT: An Emerging Dilemma and Suggestions for Management. AJR Am J Roentgenol. 2021 Oct;217(4):975-983. [PubMed: 33646823]
24.Eifer M, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Shams J, Keret N, Gorfine M, Eshet Y. COVID-19 mRNA Vaccination: Age and Immune Status and Its Association with Axillary Lymph Node PET/CT Uptake. J Nucl Med. 2022 Jan;63(1):134-139. [PMC free article: PMC8717182] [PubMed: 33893188]
25.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 15, 2023. Fludeoxyglucose F18. [PubMed: 30000776]
26.Lee DY, Lee JJ, Kwon HS, Moon WY, Jin SY, Lee SJ, Oh SJ, Ryu JS. An unusual case of anaphylaxis after fluorine-18-labeled fluorodeoxyglucose injection. Nucl Med Mol Imaging. 2013 Sep;47(3):201-4. [PMC free article: PMC4035188] [PubMed: 24900108]
27.Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, Glanville J, McIntosh H, Renehan A, Weller D, Dunlop M. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. [PMC free article: PMC4781061] [PubMed: 21958472]
28.Apostolova I, Lange C, Suppa P, Spies L, Klutmann S, Adam G, Grothe MJ, Buchert R., Alzheimer’s Disease Neuroimaging Initiative. Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1417-1422. [PubMed: 29502311]
29.Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ., European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. [PMC free article: PMC4315529] [PubMed: 25452219]
30.Sprinz C, Zanon M, Altmayer S, Watte G, Irion K, Marchiori E, Hochhegger B. Effects of blood glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an analysis on 5623 patients. Sci Rep. 2018 Feb 01;8(1):2126. [PMC free article: PMC5794870] [PubMed: 29391555]
31.Slart RHJA., Writing group. Reviewer group. Members of EANM Cardiovascular. Members of EANM Infection & Inflammation. Members of Committees, SNMMI Cardiovascular. Members of Council, PET Interest Group. Members of ASNC. EANM Committee Coordinator. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1250-1269. [PMC free article: PMC5954002] [PubMed: 29637252]
32.Dai KS, Tai DY, Ho P, Chen CC, Peng WC, Chen ST, Hsu CC, Liu YP, Hsieh HC, Yang CC, Tsai MC, Mao SJ. Accuracy of the EasyTouch blood glucose self-monitoring system: a study of 516 cases. Clin Chim Acta. 2004 Nov;349(1-2):135-41. [PubMed: 15469866]
33.Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, Jehanno N, Kurch L, Pandit-Taskar N, Parisi M, Piccardo A, Seghers V, Shulkin BL, Zucchetta P, Lim R. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0. J Nucl Med. 2021 Jan;62(1):99-110. [PMC free article: PMC8679588] [PubMed: 33334912]
